nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—CARTPT—nerve—amyotrophic lateral sclerosis	0.0461	0.113	CbGeAlD
Amphetamine—CARTPT—hindbrain—amyotrophic lateral sclerosis	0.0345	0.0848	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.0316	0.111	CbGpPWpGaD
Amphetamine—CARTPT—brainstem—amyotrophic lateral sclerosis	0.0198	0.0486	CbGeAlD
Amphetamine—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.0193	0.0625	CcSEcCtD
Amphetamine—SLC18A2—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.016	0.0564	CbGpPWpGaD
Amphetamine—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.0141	0.0458	CcSEcCtD
Amphetamine—SLC22A3—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.0139	0.0488	CbGpPWpGaD
Amphetamine—CARTPT—medulla oblongata—amyotrophic lateral sclerosis	0.0138	0.0339	CbGeAlD
Amphetamine—SLC6A4—Synaptic Vesicle Pathway—UNC13A—amyotrophic lateral sclerosis	0.0125	0.0441	CbGpPWpGaD
Amphetamine—CARTPT—spinal cord—amyotrophic lateral sclerosis	0.0123	0.0302	CbGeAlD
Amphetamine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.0119	0.0291	CbGeAlD
Amphetamine—SLC22A3—tongue—amyotrophic lateral sclerosis	0.0109	0.0268	CbGeAlD
Amphetamine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.0107	0.0348	CcSEcCtD
Amphetamine—CARTPT—nervous system—amyotrophic lateral sclerosis	0.0104	0.0255	CbGeAlD
Amphetamine—TAAR1—nervous system—amyotrophic lateral sclerosis	0.0104	0.0255	CbGeAlD
Amphetamine—MAOB—nerve—amyotrophic lateral sclerosis	0.0103	0.0254	CbGeAlD
Amphetamine—TAAR1—central nervous system—amyotrophic lateral sclerosis	0.00999	0.0245	CbGeAlD
Amphetamine—CARTPT—central nervous system—amyotrophic lateral sclerosis	0.00999	0.0245	CbGeAlD
Amphetamine—Injury—Riluzole—amyotrophic lateral sclerosis	0.00987	0.032	CcSEcCtD
Amphetamine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00979	0.0317	CcSEcCtD
Amphetamine—CARTPT—cerebellum—amyotrophic lateral sclerosis	0.00976	0.024	CbGeAlD
Amphetamine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00956	0.0235	CbGeAlD
Amphetamine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.009	0.0292	CcSEcCtD
Amphetamine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00893	0.029	CcSEcCtD
Amphetamine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.00888	0.0218	CbGeAlD
Amphetamine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00886	0.0287	CcSEcCtD
Amphetamine—DRD2—nerve—amyotrophic lateral sclerosis	0.00872	0.0214	CbGeAlD
Amphetamine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.0086	0.0279	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.00839	0.0295	CbGpPWpGaD
Amphetamine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00814	0.02	CbGeAlD
Amphetamine—CARTPT—brain—amyotrophic lateral sclerosis	0.00793	0.0195	CbGeAlD
Amphetamine—MAOB—hindbrain—amyotrophic lateral sclerosis	0.00774	0.019	CbGeAlD
Amphetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00751	0.0264	CbGpPWpGaD
Amphetamine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00722	0.0234	CcSEcCtD
Amphetamine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00716	0.0232	CcSEcCtD
Amphetamine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.0071	0.023	CcSEcCtD
Amphetamine—Depression—Riluzole—amyotrophic lateral sclerosis	0.00697	0.0226	CcSEcCtD
Amphetamine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00689	0.0223	CcSEcCtD
Amphetamine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00685	0.0222	CcSEcCtD
Amphetamine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.0068	0.022	CcSEcCtD
Amphetamine—SLC18A2—brainstem—amyotrophic lateral sclerosis	0.00673	0.0165	CbGeAlD
Amphetamine—Sweating—Riluzole—amyotrophic lateral sclerosis	0.0067	0.0217	CcSEcCtD
Amphetamine—DRD2—hindbrain—amyotrophic lateral sclerosis	0.00653	0.016	CbGeAlD
Amphetamine—MAOB—Dopamine metabolism—SOD1—amyotrophic lateral sclerosis	0.00642	0.0226	CbGpPWpGaD
Amphetamine—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00594	0.0192	CcSEcCtD
Amphetamine—SLC6A3—Parkinsons Disease Pathway—ATXN2—amyotrophic lateral sclerosis	0.00591	0.0208	CbGpPWpGaD
Amphetamine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00536	0.0174	CcSEcCtD
Amphetamine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00531	0.0172	CcSEcCtD
Amphetamine—SLC22A3—embryo—amyotrophic lateral sclerosis	0.00523	0.0128	CbGeAlD
Amphetamine—SLC18A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00521	0.0183	CbGpPWpGaD
Amphetamine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00512	0.0166	CcSEcCtD
Amphetamine—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00509	0.0125	CbGeAlD
Amphetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00505	0.0178	CbGpPWpGaD
Amphetamine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00502	0.0163	CcSEcCtD
Amphetamine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00499	0.0162	CcSEcCtD
Amphetamine—MAOB—embryo—amyotrophic lateral sclerosis	0.00484	0.0119	CbGeAlD
Amphetamine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00483	0.0157	CcSEcCtD
Amphetamine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00473	0.0153	CcSEcCtD
Amphetamine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00472	0.0153	CcSEcCtD
Amphetamine—SLC18A2—medulla oblongata—amyotrophic lateral sclerosis	0.00469	0.0115	CbGeAlD
Amphetamine—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00466	0.0115	CbGeAlD
Amphetamine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00465	0.0151	CcSEcCtD
Amphetamine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00464	0.015	CcSEcCtD
Amphetamine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00455	0.0148	CcSEcCtD
Amphetamine—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—amyotrophic lateral sclerosis	0.00448	0.0157	CbGpPWpGaD
Amphetamine—SLC18A2—Neurotransmitter Release Cycle—CHAT—amyotrophic lateral sclerosis	0.00447	0.0157	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00446	0.0145	CcSEcCtD
Amphetamine—MAOB—brainstem—amyotrophic lateral sclerosis	0.00443	0.0109	CbGeAlD
Amphetamine—Infection—Riluzole—amyotrophic lateral sclerosis	0.00443	0.0144	CcSEcCtD
Amphetamine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00435	0.0141	CcSEcCtD
Amphetamine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00431	0.014	CcSEcCtD
Amphetamine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00425	0.0138	CcSEcCtD
Amphetamine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00411	0.0101	CbGeAlD
Amphetamine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00403	0.0131	CcSEcCtD
Amphetamine—SLC18A2—Neurotransmitter Release Cycle—SLC6A1—amyotrophic lateral sclerosis	0.00398	0.014	CbGpPWpGaD
Amphetamine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00398	0.0129	CcSEcCtD
Amphetamine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00396	0.0129	CcSEcCtD
Amphetamine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00393	0.0127	CcSEcCtD
Amphetamine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00392	0.00963	CbGeAlD
Amphetamine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00388	0.0126	CcSEcCtD
Amphetamine—SLC6A4—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00387	0.0136	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00385	0.0125	CcSEcCtD
Amphetamine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00385	0.0125	CcSEcCtD
Amphetamine—SLC18A2—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.00382	0.0135	CbGpPWpGaD
Amphetamine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00381	0.0124	CcSEcCtD
Amphetamine—DRD2—brainstem—amyotrophic lateral sclerosis	0.00374	0.00919	CbGeAlD
Amphetamine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00365	0.0118	CcSEcCtD
Amphetamine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00354	0.0115	CcSEcCtD
Amphetamine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00353	0.0114	CcSEcCtD
Amphetamine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00353	0.0114	CcSEcCtD
Amphetamine—SLC18A2—nervous system—amyotrophic lateral sclerosis	0.00353	0.00866	CbGeAlD
Amphetamine—SLC6A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00351	0.0123	CbGpPWpGaD
Amphetamine—SLC18A2—central nervous system—amyotrophic lateral sclerosis	0.00339	0.00833	CbGeAlD
Amphetamine—SLC6A2—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00333	0.0117	CbGpPWpGaD
Amphetamine—SLC18A2—cerebellum—amyotrophic lateral sclerosis	0.00332	0.00814	CbGeAlD
Amphetamine—SLC22A3—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.00331	0.0116	CbGpPWpGaD
Amphetamine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00329	0.0107	CcSEcCtD
Amphetamine—DRD2—Hypothetical Network for Drug Addiction—GRIA2—amyotrophic lateral sclerosis	0.00324	0.0114	CbGpPWpGaD
Amphetamine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.0032	0.0104	CcSEcCtD
Amphetamine—SLC6A4—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00317	0.0112	CbGpPWpGaD
Amphetamine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00316	0.00777	CbGeAlD
Amphetamine—SLC6A3—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.00311	0.0109	CbGpPWpGaD
Amphetamine—MAOB—medulla oblongata—amyotrophic lateral sclerosis	0.00309	0.00759	CbGeAlD
Amphetamine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00989	CcSEcCtD
Amphetamine—SLC6A4—Synaptic Vesicle Pathway—SLC1A3—amyotrophic lateral sclerosis	0.00299	0.0105	CbGpPWpGaD
Amphetamine—CYP2A6—cerebellum—amyotrophic lateral sclerosis	0.00296	0.00727	CbGeAlD
Amphetamine—SLC6A3—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00295	0.0104	CbGpPWpGaD
Amphetamine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00956	CcSEcCtD
Amphetamine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.0029	0.00712	CbGeAlD
Amphetamine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00286	0.00703	CbGeAlD
Amphetamine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00919	CcSEcCtD
Amphetamine—Rash—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00912	CcSEcCtD
Amphetamine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00911	CcSEcCtD
Amphetamine—Headache—Riluzole—amyotrophic lateral sclerosis	0.00279	0.00906	CcSEcCtD
Amphetamine—MAOB—spinal cord—amyotrophic lateral sclerosis	0.00276	0.00677	CbGeAlD
Amphetamine—SLC18A2—brain—amyotrophic lateral sclerosis	0.00269	0.00662	CbGeAlD
Amphetamine—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00267	0.00655	CbGeAlD
Amphetamine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00265	0.00859	CcSEcCtD
Amphetamine—CYP2D6—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.0026	0.00916	CbGpPWpGaD
Amphetamine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00257	0.0063	CbGeAlD
Amphetamine—SLC22A3—nervous system—amyotrophic lateral sclerosis	0.00251	0.00616	CbGeAlD
Amphetamine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00251	0.00616	CbGeAlD
Amphetamine—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00244	0.006	CbGeAlD
Amphetamine—SLC22A5—medulla oblongata—amyotrophic lateral sclerosis	0.00243	0.00596	CbGeAlD
Amphetamine—SLC22A3—central nervous system—amyotrophic lateral sclerosis	0.00242	0.00593	CbGeAlD
Amphetamine—CYP2A6—brain—amyotrophic lateral sclerosis	0.00241	0.00591	CbGeAlD
Amphetamine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00235	0.00578	CbGeAlD
Amphetamine—MAOB—nervous system—amyotrophic lateral sclerosis	0.00232	0.0057	CbGeAlD
Amphetamine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00225	0.00552	CbGeAlD
Amphetamine—MAOB—central nervous system—amyotrophic lateral sclerosis	0.00224	0.00549	CbGeAlD
Amphetamine—MAOB—cerebellum—amyotrophic lateral sclerosis	0.00219	0.00537	CbGeAlD
Amphetamine—SLC22A5—spinal cord—amyotrophic lateral sclerosis	0.00217	0.00532	CbGeAlD
Amphetamine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00215	0.00528	CbGeAlD
Amphetamine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00207	0.00509	CbGeAlD
Amphetamine—SLC6A3—brain—amyotrophic lateral sclerosis	0.00204	0.005	CbGeAlD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00204	0.00717	CbGpPWpGaD
Amphetamine—DRD2—nervous system—amyotrophic lateral sclerosis	0.00196	0.00481	CbGeAlD
Amphetamine—DRD2—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00194	0.00683	CbGpPWpGaD
Amphetamine—SLC22A3—brain—amyotrophic lateral sclerosis	0.00192	0.00471	CbGeAlD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.0019	0.00668	CbGpPWpGaD
Amphetamine—DRD2—central nervous system—amyotrophic lateral sclerosis	0.00189	0.00463	CbGeAlD
Amphetamine—SLC6A4—brain—amyotrophic lateral sclerosis	0.00187	0.00459	CbGeAlD
Amphetamine—DRD2—cerebellum—amyotrophic lateral sclerosis	0.00184	0.00453	CbGeAlD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00184	0.00647	CbGpPWpGaD
Amphetamine—MAOB—brain—amyotrophic lateral sclerosis	0.00178	0.00436	CbGeAlD
Amphetamine—SLC6A3—Parkinsons Disease Pathway—CASP9—amyotrophic lateral sclerosis	0.00177	0.00623	CbGpPWpGaD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00176	0.0062	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00176	0.00618	CbGpPWpGaD
Amphetamine—SLC22A5—cerebellum—amyotrophic lateral sclerosis	0.00172	0.00422	CbGeAlD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00169	0.00595	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.00165	0.00579	CbGpPWpGaD
Amphetamine—SLC6A2—brain—amyotrophic lateral sclerosis	0.00164	0.00404	CbGeAlD
Amphetamine—SLC6A4—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00157	0.00553	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00156	0.00549	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.00151	0.0053	CbGpPWpGaD
Amphetamine—DRD2—brain—amyotrophic lateral sclerosis	0.0015	0.00368	CbGeAlD
Amphetamine—TAAR1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.0014	0.00492	CbGpPWpGaD
Amphetamine—SLC22A5—brain—amyotrophic lateral sclerosis	0.0014	0.00343	CbGeAlD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.00138	0.00485	CbGpPWpGaD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00137	0.00482	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00135	0.00475	CbGpPWpGaD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—amyotrophic lateral sclerosis	0.00134	0.00471	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.0013	0.00456	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.00128	0.00451	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.00128	0.00451	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00122	0.0043	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00122	0.0043	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00122	0.0043	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00122	0.0043	CbGpPWpGaD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.00121	0.00427	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.0012	0.00421	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.0012	0.00421	CbGpPWpGaD
Amphetamine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00118	0.00289	CbGeAlD
Amphetamine—SLC18A2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.00115	0.00406	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00115	0.00404	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.00114	0.00402	CbGpPWpGaD
Amphetamine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.00113	0.00278	CbGeAlD
Amphetamine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00111	0.00272	CbGeAlD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00106	0.00372	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00106	0.00372	CbGpPWpGaD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—amyotrophic lateral sclerosis	0.00106	0.00371	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00105	0.00371	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00104	0.00365	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.00101	0.00355	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.001	0.00352	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000989	0.00348	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000982	0.00345	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000982	0.00345	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000964	0.00339	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.00093	0.00327	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000926	0.00326	CbGpPWpGaD
Amphetamine—CYP2D6—brain—amyotrophic lateral sclerosis	0.0009	0.00221	CbGeAlD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000898	0.00316	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000898	0.00316	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000895	0.00315	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000886	0.00312	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000876	0.00308	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000875	0.00308	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000843	0.00297	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000833	0.00293	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000831	0.00292	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000822	0.00289	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000822	0.00289	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000802	0.00282	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000801	0.00282	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000798	0.00281	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000794	0.00279	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000791	0.00278	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000772	0.00272	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000764	0.00269	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000764	0.00269	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000762	0.00268	CbGpPWpGaD
Amphetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—amyotrophic lateral sclerosis	0.000745	0.00262	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000732	0.00257	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000728	0.00256	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000718	0.00253	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000713	0.00251	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000699	0.00246	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000693	0.00244	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000688	0.00242	CbGpPWpGaD
Amphetamine—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000682	0.0024	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000681	0.0024	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000675	0.00238	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000648	0.00228	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000633	0.00223	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.00063	0.00221	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000623	0.00219	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000621	0.00218	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000619	0.00218	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000611	0.00215	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000609	0.00214	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000609	0.00214	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000596	0.0021	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000585	0.00206	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000585	0.00206	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000574	0.00202	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000564	0.00198	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00056	0.00197	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000557	0.00196	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000552	0.00194	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000539	0.0019	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000537	0.00189	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000535	0.00188	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000528	0.00186	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000528	0.00186	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000528	0.00186	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000526	0.00185	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000522	0.00184	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000518	0.00182	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000516	0.00181	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000515	0.00181	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000515	0.00181	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000499	0.00176	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000487	0.00171	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000485	0.00171	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000483	0.0017	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000471	0.00166	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000471	0.00166	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000457	0.00161	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000457	0.00161	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000455	0.0016	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000455	0.0016	CbGpPWpGaD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000447	0.00157	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000441	0.00155	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—DAO—amyotrophic lateral sclerosis	0.00044	0.00155	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000438	0.00154	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000429	0.00151	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000429	0.00151	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000424	0.00149	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000418	0.00147	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000412	0.00145	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000407	0.00143	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000406	0.00143	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000387	0.00136	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—DAO—amyotrophic lateral sclerosis	0.000372	0.00131	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.00037	0.0013	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000355	0.00125	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000355	0.00125	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000355	0.00125	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000345	0.00121	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000333	0.00117	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000326	0.00115	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000317	0.00111	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000316	0.00111	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000315	0.00111	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000315	0.00111	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000314	0.0011	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSR—amyotrophic lateral sclerosis	0.000308	0.00108	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000296	0.00104	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000296	0.00104	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000292	0.00103	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000282	0.000993	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.00028	0.000987	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000273	0.000962	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000271	0.000954	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000268	0.000944	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.00026	0.000916	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSR—amyotrophic lateral sclerosis	0.00026	0.000916	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000253	0.000889	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000252	0.000887	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000237	0.000834	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000235	0.000828	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000223	0.000784	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000217	0.000763	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—DAO—amyotrophic lateral sclerosis	0.000214	0.000754	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000214	0.000753	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000214	0.000752	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.00021	0.000737	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000187	0.000658	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000185	0.000652	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000184	0.000649	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000172	0.000607	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000168	0.000589	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000166	0.000585	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000166	0.000585	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000166	0.000582	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000162	0.000572	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000152	0.000535	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSR—amyotrophic lateral sclerosis	0.00015	0.000527	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000143	0.000501	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000142	0.000501	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000141	0.000497	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000136	0.000478	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000133	0.000468	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000131	0.000459	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000125	0.000439	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000123	0.000433	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000123	0.000432	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	0.00012	0.000423	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000116	0.000409	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000115	0.000404	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000113	0.000397	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	0.00011	0.000386	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000106	0.000372	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	0.000104	0.000365	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOE—amyotrophic lateral sclerosis	0.000103	0.000361	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000101	0.000356	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.0001	0.000352	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	9.9e-05	0.000348	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.31e-05	0.000327	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	9.11e-05	0.000321	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOE—amyotrophic lateral sclerosis	8.69e-05	0.000306	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	8.41e-05	0.000296	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.27e-05	0.000291	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.05e-05	0.000283	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.31e-05	0.000257	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.04e-05	0.000248	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.03e-05	0.000247	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	6.9e-05	0.000243	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.8e-05	0.000239	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.62e-05	0.000233	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.38e-05	0.000224	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.08e-05	0.000214	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.07e-05	0.000214	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.95e-05	0.000209	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.2e-05	0.000183	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOE—amyotrophic lateral sclerosis	5e-05	0.000176	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.89e-05	0.000172	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.32e-05	0.000152	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.02e-05	0.000141	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.71e-05	0.000131	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.43e-05	0.000121	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.41e-05	0.00012	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.32e-05	0.000117	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	2.81e-05	9.87e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.56e-05	9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.42e-05	8.5e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.17e-05	7.64e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.92e-05	6.76e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.64e-05	5.77e-05	CbGpPWpGaD
